Hemophilia Archives

liver anatomy organs Sebastian Kaulitzki fi

News and Trends 21 Nov 2016

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […]

November 21, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Nov 2016

Roche hits a Speed Bump on the way to a Hemophilia Cure

The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […]

November 4, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 29 Jul 2016

Gene Therapy for severe Hemophilia has new Phase I/II Results

uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia B, a rare genetic disorder. After 9 months, the therapy maintains 75% reduction of transfusions. A good sign for the therapy’s durability. Although quite rare (1 in 20,000 male births), Hemophilia B is famous for being spread in European royal […]

July 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

sobi hemophilia clotting factor alprolix

News and Trends 17 May 2016

Rare Disease Biopharma can now sell Hemophilia treatment across whole of EU

Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy that protects hemophilia B patients from uncontrolled bleeding. With a focus on rare diseases, Swedish Orphan Biovitrum (Sobi) has clinical programmes in diseases like alkaptonuria, tyrosinaemia and hemophilia – a disease with which Sobi is particularly invested. Its candidate for hemophilia […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 13 Oct 2015

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish Orphan Biovitrum AB (SOBI) from Stockholm via the World Federation of Hemophilia (WFH)’s AID project. The relief effort pledges to ship over 1 billion units […]

October 13, 2015 - 3 minutesmins - By Dani Bancroft

glycotope ocotopharm key partnership e1457433449611

News and Trends 9 Oct 2015

Key-partnership for the most well-funded Biotech in Berlin

Berlin is growing as a massive Biotech hub, in part thanks to prestigious University of Medicine here (Charité), which is flanked by other world-class institutions (Humboldt University, Technische, Free University of Berlin etc.) and a thriving start-up scene. The most well-funded Biotech here at the moment is Glycotope, a biotech which has raised over €135M […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Sep 2015

Apitope relocates to Wales after €12M series B financing round

Now, as we’ve recently discussed here at Labiotech, there doesn’t appear to be many Welsh biotechs…however, this is all about to change, with major Autoimmune disease focused Apitope relocating it’s HQ to Wales. This is following a €12M series B fundraiser led by the Wales Lifesciences Fund for its monoclonal antibody pipeline. Aptiope are currently […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Aug 2015

Sobi gets a long-lasting grip on a rare type of Hemophilia

In the 19th century, Queen Victoria passed the Hemophilia B to diverse royal houses of Europe. Today, its characteristic heavy bleedings can be treated quite well, as Swedish Orphan Biovitrum (Sobi) and its partner Biogen showed in the results of an ongoing long-term study. Sobi was formed in 2001 through a fusion of several units […]

August 19, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 9 Jun 2015

Apitope’s peptide to take on Haemophilia A

Apitope’s pre-clinical candidate ATX-F8-117 has been granted Orphan Drug Status by the US FDA for the treatment of Haemophilia A. The drug candidate already obtained an Orphan Drug Designation by the European Medical Agency last year. The compound also awakened the interest of Abzena, which works with Apitope to design the candidate. Haemophilia A is […]

June 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us